jeudi 20 avril 2017

Onco Actu du 20 avril 2017

3.1 Tabac

De Blasio Backs Plan to Lift Base Price of Pack of Cigarettes to $13 [NY Times]

3.1.1 Tabac - e-cigs

Big Tobacco Attacks Sensible F.D.A. Rules on Vaping [NY Times]

3.6 Prévention - Activité physique

Cycling to work can cut cancer and heart disease, says study [BBC News]

3.7 Alcool

Ad linking alcohol to cancer most effective at curbing drinking, study finds [The Guardian]

4. Dépistage, diagnostic et pronostic

Noninvasive Imaging Test Shown Accurate in Ruling out Kidney Cancers [Johns Hopkins]

4.2 Dép., diag. & prono. - Génome

Do patients and doctors understand breast cancer genetic testing results? [Reuters]

5. Traitements

Taking advantage of cancers’ abnormal metabolism could lead to a new way to ‘starve’ tumours [Cancer Research UK]

Billion-dollar project would synthesize hundreds of thousands of molecules in search of new medicines [Science]

Controlled amino acid diet 'could help cancer treatment' [BBC News]

5.12.1 Immunothérapies - partenariats

Bristol-Myers preps second checkpoint/cancer vax combo study under its $1B Bavarian Nordic pact [EndPoints]

5.12.5 Immunothérapies - Pharma

As AstraZeneca chases rivals, immuno-oncology gets complicated [Reuters]

5.2 Pharma

AbbVie PARP inhibitor veliparib flunks two phase 3 trials [FierceBiotech]

AbbVie grapples with another setback as 2 PhIII trials for its PARP veliparib flop [AbbVie]

AbbVie Announces Topline Results from Two Phase 3 Studies Investigating Veliparib in Combination with Chemotherapy for the Treatment of Patients with Advanced or Metastatic Squamous Non-Small Cell Lung Cancer and Early-Stage Triple-Negative Breast Cancer [AbbVie]

AbbVie cancer drug fails two late-stage trials [Reuters]

5.2.1 Pharma - Partenariats

Lion Biotechnologies teams up with MD Anderson Cancer Center on TIL tech [FierceBiotech]

5.2.3 Pharma - économie

Meet the lawyer trying to pry drug pricing secrets out of Big Pharma [STAT]

5.3 Traitements - FDA, EMA, NICE...

EU crushes U.K. hopes of retaining EMA after Brexit [FierceBiotech]

5.4 Traitements - Economie

TESARO Announces Availability of Zejula™ (Niraparib) for Patients With Recurrent Ovarian Cancer in the U.S. [Tesaro]

Tesaro Resorts to PR Razzle Dazzle to Make Ovarian Cancer Drug Appear Cheaply Priced [The Street]

Is Tesaro playing a pricing game with Zejula? Not at all, says the CEO. And here’s why [EndPoints]

6.1 Observation

In the news race to report CDC’s numbers on HPV infection rates, some important context was missing [HealthNewsReview]

6.6 Publications

Want to Fix Science’s Replication Crisis? Then Replicate [Wired]

6.7 DMP, Big Data & applis

Verily’s Baseline: Homemade Wearable and Limited Data Sharing [Xconomy]

Verily kicks off Baseline study, which seeks to define ‘health’ [FierceBiotech]

Verily Says “We Grew Up”. We’ll See. [In the Pipeline]

Google Offshoot Starts A 10,000-Person Study To Plumb Human Biology [Forbes]

Alphabet seeks 10,000 volunteers — and their health data — for a massive medical study [The Verge]

Google’s Massive Health Study Seeks 10,000 Volunteers to Give Up Their Medical Secrets [MIT Technology Review]

Google’s Health Moonshot Comes Back to Earth [Bloomberg]